Qiagen inks deal to buy Corbett

Qiagen is buying Corbett Life Science for $70 million down in cash and stock and another $65 million in milestones. Corbett manufactures and distributes life sciences instrumentation. Corbett is best known for the first rotary, real-time PCR cycler system--the Rotor-Gene. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.